SENS vs. MLAB, QURE, CHRS, ELYM, AGEN, PBYI, TSVT, FHTX, GTHX, and CDT
Should you be buying Senseonics stock or one of its competitors? The main competitors of Senseonics include Mesa Laboratories (MLAB), uniQure (QURE), Coherus BioSciences (CHRS), Eliem Therapeutics (ELYM), Agenus (AGEN), Puma Biotechnology (PBYI), 2seventy bio (TSVT), Foghorn Therapeutics (FHTX), G1 Therapeutics (GTHX), and Conduit Pharmaceuticals (CDT). These companies are all part of the "medical" sector.
Mesa Laboratories (NASDAQ:MLAB) and Senseonics (NYSE:SENS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.
Mesa Laboratories has higher revenue and earnings than Senseonics. Senseonics is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.
Mesa Laboratories has a net margin of 0.45% compared to Mesa Laboratories' net margin of -346.38%. Senseonics' return on equity of 7.41% beat Mesa Laboratories' return on equity.
Mesa Laboratories has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Senseonics has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.
Mesa Laboratories received 216 more outperform votes than Senseonics when rated by MarketBeat users. Likewise, 63.82% of users gave Mesa Laboratories an outperform vote while only 16.67% of users gave Senseonics an outperform vote.
In the previous week, Senseonics had 11 more articles in the media than Mesa Laboratories. MarketBeat recorded 12 mentions for Senseonics and 1 mentions for Mesa Laboratories. Mesa Laboratories' average media sentiment score of 0.40 beat Senseonics' score of 0.00 indicating that Senseonics is being referred to more favorably in the news media.
Mesa Laboratories currently has a consensus price target of $130.00, suggesting a potential upside of 6.37%. Senseonics has a consensus price target of $1.25, suggesting a potential upside of 157.68%. Given Mesa Laboratories' higher possible upside, analysts plainly believe Senseonics is more favorable than Mesa Laboratories.
90.6% of Mesa Laboratories shares are owned by institutional investors. Comparatively, 12.4% of Senseonics shares are owned by institutional investors. 5.2% of Mesa Laboratories shares are owned by company insiders. Comparatively, 3.9% of Senseonics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Mesa Laboratories beats Senseonics on 12 of the 17 factors compared between the two stocks.
Get Senseonics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SENS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Senseonics Competitors List
Related Companies and Tools
